Lau CP - Search Results

1

Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.

Ma BB, Lui VW, Cheung CS, Lau CP, Ho K, Hui EP, Tsui SK, Ng MH, Cheng SH, Ng PK, Tsao SW, Chan AT. Ma BB, et al. Among authors: lau cp. Invest New Drugs. 2013 Feb;31(1):30-8. doi: 10.1007/s10637-012-9828-4. Epub 2012 May 8. Invest New Drugs. 2013. PMID: 22565394

2

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.

Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Chan AT. Ma BB, et al. Among authors: lau cp. Invest New Drugs. 2010 Aug;28(4):413-20. doi: 10.1007/s10637-009-9269-x. Epub 2009 May 27. Invest New Drugs. 2010. PMID: 19471857

3

Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT. Hui EP, et al. Among authors: lau cp. Invest New Drugs. 2011 Dec;29(6):1123-31. doi: 10.1007/s10637-010-9451-1. Epub 2010 May 15. Invest New Drugs. 2011. PMID: 20467883

4

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines.

Ma BB, Lui VW, Hui CW, Lau CP, Wong CH, Hui EP, Ng MH, Tsao SW, Li Y, Chan AT. Ma BB, et al. Among authors: lau cp. Invest New Drugs. 2013 Jun;31(3):567-75. doi: 10.1007/s10637-012-9896-5. Epub 2012 Nov 11. Invest New Drugs. 2013. PMID: 23143779

5

Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.

Chan SL, Wong CH, Lau CP, Zhou Q, Hui CW, Lui VW, Ma BB, Chan AT, Yeo W. Chan SL, et al. Among authors: lau cp. Cancer Chemother Pharmacol. 2013 Jun;71(6):1417-25. doi: 10.1007/s00280-013-2139-4. Epub 2013 Apr 2. Cancer Chemother Pharmacol. 2013. PMID: 23546591

6

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.

Wong CH, Loong HH, Hui CW, Lau CP, Hui EP, Ma BB, Chan AT. Wong CH, et al. Among authors: lau cp. Invest New Drugs. 2013 Dec;31(6):1399-408. doi: 10.1007/s10637-013-0007-z. Epub 2013 Aug 24. Invest New Drugs. 2013. PMID: 23975511

7

Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models.

Ma BB, Lui VW, Hui CW, Lau CP, Wong CH, Hui EP, Ng MH, Cheng SH, Tsao SW, Tsang CM, Cheung CS, Ho K, Chan AT. Ma BB, et al. Among authors: lau cp. Cancer Lett. 2014 Feb 1;343(1):24-32. doi: 10.1016/j.canlet.2013.09.007. Epub 2013 Sep 14. Cancer Lett. 2014. PMID: 24041865

8

Case of chlorambucil-induced seizure.

Lau CP, Ma B, Chan AT. Lau CP, et al. Intern Med J. 2006 Oct;36(10):683-4. doi: 10.1111/j.1445-5994.2006.01191.x. Intern Med J. 2006. PMID: 16958652 No abstract available.

9

Comparative Evaluation of Activity Sensing Rate Responses of a Leadless Pacemaker Using Intracardiac Accelerometer Versus Traditional Activity Sensing Pacemaker.

Hai JJ, Lau CP, Tse HF. Hai JJ, et al. Among authors: lau cp. Circ Arrhythm Electrophysiol. 2024 Apr;17(4):e012616. doi: 10.1161/CIRCEP.123.012616. Epub 2024 Mar 18. Circ Arrhythm Electrophysiol. 2024. PMID: 38497210 No abstract available.

10

Pacing induced tricuspid regurgitation: Does the lead matter?

Yiu KK, Lau CP. Yiu KK, et al. Among authors: lau cp. J Cardiovasc Electrophysiol. 2023 Nov;34(11):2243-2245. doi: 10.1111/jce.16114. Epub 2023 Oct 23. J Cardiovasc Electrophysiol. 2023. PMID: 37870154 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

733 results

Search Page